The Biotech Growth Trust (LON:BIOG) Shares Cross Below Fifty Day Moving Average – Time to Sell?

The Biotech Growth Trust PLC (LON:BIOG) passed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of GBX 886.16 ($11.03) and traded as low as GBX 875 ($10.89). The Biotech Growth Trust shares last traded at GBX 881 ($10.97), with a volume of 164,870 shares changing hands.

The Biotech Growth Trust Stock Up 0.1 %

The company has a debt-to-equity ratio of 13.03, a current ratio of 0.33 and a quick ratio of 0.00. The firm’s 50-day moving average price is GBX 886.16 and its 200 day moving average price is GBX 971.53. The firm has a market capitalization of £283.39 million, a price-to-earnings ratio of 426.09 and a beta of 0.50.

The Biotech Growth Trust (LON:BIOG) last announced its earnings results on Wednesday, November 27th. The company reported GBX 0.20 ($0.00) EPS for the quarter. The Biotech Growth Trust had a return on equity of 21.57% and a net margin of 92.85%.

Insider Activity at The Biotech Growth Trust

In other The Biotech Growth Trust news, insider Julie Tankard purchased 1,022 shares of the firm’s stock in a transaction on Wednesday, December 4th. The shares were purchased at an average cost of GBX 972 ($12.10) per share, with a total value of £9,933.84 ($12,367.83). Also, insider Nicola Shepherd acquired 1,000 shares of the company’s stock in a transaction dated Monday, January 13th. The shares were bought at an average cost of GBX 846 ($10.53) per share, with a total value of £8,460 ($10,532.87). In the last quarter, insiders bought 6,222 shares of company stock valued at $5,659,584. 0.71% of the stock is owned by insiders.

About The Biotech Growth Trust

The Biotech Growth Trust seeks capital appreciation through investment in the worldwide biotechnology industry. In order to achieve its investment objective, the Company invests in a diversified portfolio of shares and related securities in biotechnology companies on a worldwide basis. Performance is measured against the NASDAQ Biotechnology Index (sterling adjusted).